Dr Ciaran Kohli-Lynch

  • Visiting Research Assistant (School of Health & Wellbeing)


List by: Type | Date

Jump to: 2022 | 2020 | 2019
Number of items: 4.


Kohli-Lynch, C. N., Lewsey, J. , Boyd, K. A. , French, D. D., Jordan, N., Moran, A. E., Sattar, N. , Preiss, D. and Briggs, A. H. (2022) Beyond 10-year risk: a cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease. Circulation, 145(17), pp. 1312-1323. (doi: 10.1161/CIRCULATIONAHA.121.057631) (PMID:35249370) (PMCID:PMC9022692)

Xin, Y. , Gray, E., Robles-Zurita, J. A., Haghpanahan, H. , Heggie, R., Kohli-Lynch, C., Briggs, A. , McAllister, D. A. , Lawson, K. D. and Lewsey, J. (2022) From spreadsheets to script: experiences from converting a Scottish cardiovascular disease policy model into R. Applied Health Economics and Health Policy, 20(2), pp. 149-158. (doi: 10.1007/s40258-021-00684-y) (PMID:34671930)


Kohli-Lynch, C., Thanassoulis, G., Moran, A. and Sniderman, A. D. (2020) The clinical utility of apoB versus LDL-C/non-HDL-C. Clinica Chimica Acta, 508, pp. 103-108. (doi: 10.1016/j.cca.2020.05.001) (PMID:32387091)


Kohli-Lynch, C. N., Bellows, B. K., Thanassoulis, G., Zhang, Y., Pletcher, M. J., Vittinghoff, E., Pencina, M. J., Kazi, D., Sniderman, A. D. and Moran, A. E. (2019) Cost-effectiveness of low-density lipoprotein cholesterol level–guided statin treatment in patients with borderline cardiovascular risk. JAMA Cardiology, 4(10), pp. 969-977. (doi: 10.1001/jamacardio.2019.2851)

This list was generated on Sat Jun 3 12:49:45 2023 BST.